Taking the Guesswork out of GI Motility Evaluation

Gastrointestinal motility is key to multiple disorders  and dysfunctions experienced by tens of millions in the US. Yet existing measurement approaches are inadequate, typically requiring invasive procedures to assess a single organ for a few hours in a clinical setting.

G-Tech’s breakthrough GutTracker, in contrast, measures GI motility of the stomach, small intestine and colon non-invasively over multiple days as patients go about their normal daily lives.

A person in a white dress holds their stomach where a graphic of a gut is drawn in white.


GutTracker consists of wireless, wearable electrode patches that read electrical signals at the skin surface, a smartphone app that collects the raw data from the patches via Bluetooth LE and sends it to a cloud server, and data analysis algorithms that process and quantify the motor activity of the digestive organs. GutTracker is  an FDA-cleared medical device that must be used under the supervision of physicians. 

Three patches placed on a person's stomach.

Like an EKG for the Gut

The GutTracker patches detect myoelectric signals produced by the GI system in a similar fashion to how EKG patches detect electric signals from the heart. The GI signals are assigned to each organ based on frequency. For instance, the stomach has a well-known rhythmic frequency of 3 cycles per minute that appears as an easily identifiable narrow peak in the frequency spectrum.

Multi-day, noninvasive motility signals provide new information to help physicians assess a patient’s condition. For example, the GutTracker provides overall activity of each organ, helping clinicians determine whether each organ’s motility is low, high or normal. 

Graph of activity on the y-axis from 0 to 100,000 and frequency on the x-axis from 0 to 27. From 3-4, 5-12, and 12-28 on the x-axis, there are peeks on the y-axis.

Current Status

Over 800 patients have been tested with GutTracker in clinical studies at leading US hospitals. G-Tech has published 5 clinical articles and given over 30 presentations at medical conferences.  The product has received 510(k) clearance from the US FDA but is not yet commercially available as extensive clinical studies are still underway. Current areas of research focus include Gastroparesis Syndrome, Crohn’s Disease, constipation and patients recovering from abdominal surgeries.

Watch the G-Tech Team Describe their Mission in a Video Produced by the Kenneth Rainin Foundation

For more information, please contact us at info@gtechmedical.com.